TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16831952
Drug: Daily ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ibandronate
Study: 8401546
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for 8 weeks
Study: 8401546
Drug: Intensive psychological,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive psychological, pharmacologic, and experimental treatment approaches
Study: 25618476
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy
Study: 16481707
Drug: 5% permethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% permethrin cream
Study: 22905702
Drug: 1% lindane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lindane lotion
Study: 21253453
Drug: FFNS 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFNS 110 mcg once daily
Study: 7854360
Drug: Whitfield's cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitfield's cream (3% salicylic acid and 6% benzoylic acid)
Study: 1096122
Drug: Clotrimazole cream
Normalized name: Clotrimazole Cream
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole cream
Study: 4330318
Drug: Lysostaphin nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysostaphin nasal spray
Study: 4330318
Drug: Neosporin ointment
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neosporin ointment
Study: 30940887
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg daily for 3–7 days)
Study: 30940887
Drug: Periocular injection
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular injection of methylprednisolone (40 mg, 1–3 days before vitrectomy)
Study: 30940887
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone in CD subsided eyes
Study: 30940887
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone in CD persistent eyes
Study: 30940887
Drug: Periocular injection
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular injection in CD subsided eyes
Study: 30940887
Drug: Periocular injection
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular injection in CD persistent eyes
Study: 26355026
Drug: High-dose lipo-PGE1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lipo-PGE1
Study: 26355026
Drug: Low-dose lipo-PGE1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lipo-PGE1
Study: 23052515
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (group G)
Study: 19692805
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment directed to the large intestine meridian (LI 8 to LI 10)
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 1, 4, and 5)
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 1, 4, and 5)
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with low viraemia)
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with low viraemia)
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with high viraemia)
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with high viraemia)
Study: 17109680
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg‐IFN) alpha‐2b (both doses) plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 2 and 3)
Study: 3652000
Drug: Mitoxantrone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 10 mg/m2 single intravenous dose
Study: 3652000
Drug: Mitoxantrone in
Normalized name: Mitoxantrone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone in five consecutive daily fractions of 2 mg/m2
Study: 3652000
Drug: Vinblastine continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine continuous intravenous infusion of 1.2 mg/m2 daily for 5 days
Study: 3652000
Drug: Mitoxantrone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone and vinblastine combination
Study: 12631557
Drug: Asimadoline 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asimadoline 0.15 mg
Study: 12950423
Drug: Asimadoline 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asimadoline 1.5 mg
Study: 8438618
Drug: 1-3 x
Normalized name: cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-3 x 10(9) c.f.u. of lyophilized vaccine, administered in three oral inoculations
Study: 8438618
Drug: Single application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of the total dose for primary immunization or booster
Study: 3503114
Drug: Pindolol 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 1% twice daily
Study: 22539077
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL, 595 nm) treatment
Study: 16026014
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity training (60 minutes per week for two weekly training sessions)
Study: 16026014
Drug: Middle intensity
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle intensity training (2 1/2 hours of training per week for 5 weekly training sessions)
Study: 12053882
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron before anaesthesia
Study: 12053882
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron at the end of anaesthesia
Study: 9833299
Drug: Intermittent ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent ondansetron (24 mg i.v. q 12 h/day)
Study: 9833299
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion ondansetron (8 mg i.v. loading dose followed by a continuous infusion of 2 mg/h per day)
Study: 17052816
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal vaccine
Study: 30415646
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal daily schedules writing)
Study: 28758542
Drug: Standard Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Group (SG) - weekly two-hour exercise session for six weeks
Study: 23055001
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment in a 2-week, double-blind, placebo-controlled trial
Study: 16838235
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir cream (topical iontophoretic application)
Study: 9106687
Drug: Preoperative hyperthermia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative hyperthermia combined with chemotherapy and irradiation (HCR therapy) followed by surgery
Study: 9106687
Drug: Preoperative hyperthermia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative hyperthermia combined with chemotherapy and irradiation (HCR therapy) plus surgery
Study: 8195847
Drug: Brodimoprim (BDP)
Normalized name: brodimoprim
DrugBank: Brodimoprim (DB13795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim (BDP) 400 mg loading dose followed by 200 mg once a day
Study: 8195847
Drug: Amoxicillin (AMX)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMX) 750 mg t.i.d
Study: 27075370
Drug: Rapid palatal
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid palatal expansion with a hyrax-type expander, activated twice a day for 15 days to obtain 7.5 mm of palatal expansion, left in situ for six months.
Study: 27075370
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, only observation).
Study: 20456813
Drug: Healthy diet+PS
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy diet+PS (2 g/d of PS)
Study: 20456813
Drug: Free diet+PS
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free diet+PS (2 g/d of PS)
Study: 10599658
Drug: 1 500-mg
Normalized name: levocarnitine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 500-mg tablet of levofloxacin (group 1, 22 patients)
Study: 10599658
Drug: 2 500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 500-mg tablets of levofloxacin (group 2, 23 patients)
Study: 7794081
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation therapy (Fluorouracil, cisplatin, and 4500 cGy over 5 weeks)
Study: 7794081
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation therapy
Study: 9124166
Drug: Sotalol 160
Normalized name: sotalol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 160 mg twice daily
Study: 11471639
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of ibuprofen
Study: 17524266
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg once daily for 12 weeks
Study: 8205603
Drug: TCV-116 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116 (2.5 mg and greater)
Study: 8205603
Drug: TCV-116 (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116 (repeated administration, once-daily for 8 days)
Study: 8205603
Drug: TCV-116 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116 (single doses)
Study: 8205603
Drug: TCV-116 (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116 (first 24 hours post-administration)
Study: 8205603
Drug: TCV-116 (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116 (repeated administration)
Study: 30561840
Drug: Baclofen (GABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (GABA B receptor agonist)
Study: 24933773
Drug: 17% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17% EDTA (used at the end of root canal preparation)
Study: 17488800
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg daily for 6 weeks
Study: 17488800
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg daily for 6 weeks
Study: 16054412
Drug: Low normal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low normal protein content (LNP) diet (10 E%; 0.9 g protein/kg body weight)
Study: 16054412
Drug: High normal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High normal protein content (HNP) diet (20 E%; 1.8 g protein/kg body weight)
Study: 12398257
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg during week 1, 100 mg during week 2, 150 mg during weeks 3, 4, and 5)
Study: 261957
Drug: Metoprolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (150 mg/die)
Study: 31424568
Drug: Any adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any adjuvant treatment
Study: 28341243
Drug: Non-preserved gel
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-preserved gel solution of carboxymethylcellulose
Study: 19500003
Drug: Powdered Nigella
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered Nigella sativa (Kalonji) seed in capsules
Study: 10051763
Drug: Buprenorphine (partial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (partial opioid agonist)
Study: 3731680
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg)
Study: 7747291
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg every 12 h for 3 days
Study: 7747291
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg every 6 h for 3 days
Study: 7747291
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid 500 mg every 6 h for 3 days
Study: 7747291
Drug: Pivmecillinam 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 500 mg every 6 h for 3 days
Study: 2106804
Drug: Continuous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ranitidine infusions
Study: 2106804
Drug: Continuous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ranitidine infusions with enteral nutrition via nasogastric tube
Study: 3221935
Drug: Levamisole immunotherapy
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole immunotherapy
Study: 27469537
Drug: 1 hand
Normalized name: Upside Down Set Vol 1 Handcare KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 hand therapy visit at 10-14 days postoperatively
Study: 24614837
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 100 mg/kg/day
Study: 19818450
Drug: 0.45% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% saline solution at 100% maintenance rate
Study: 19818450
Drug: 0.45% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% saline solution at 50% maintenance rate
Study: 19818450
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution at 100% maintenance rate
Study: 19818450
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution at 50% maintenance rate
Study: 19818450
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration rate
Study: 15694213
Drug: IMPACT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IMPACT intervention (multidisciplinary depression treatment program with care manager support)
Study: 12001042
Drug: Continuation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation with protease inhibitor plus nucleoside-analogue combination regimens (n=79)
Study: 7768298
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (200 micrograms) administered twice daily for 2 weeks
Study: 2180106
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 40 mg per day for 14 days
Study: 2180106
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate 500 micrograms thrice daily for 14 days
Study: 7256808
Drug: Combined radiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiotherapy schemes (external and intracavitary radiations given alternately with unequal doses)
Study: 7256808
Drug: Modified approximate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified approximate CRE and nominal dose methods
Study: 16945514
Drug: 5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/kg of pentastarch (group A)
Study: 16945514
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg of pentastarch (group B)
Study: 10987233
Drug: Postmastectomy radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiotherapy and systemic treatment
Study: 22431703
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment alone
Study: 8800358
Drug: 4% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% CO2 inhalation during exhaustive maximal two‐legged cycling
Study: 8800358
Drug: No CO2
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No CO2 inhalation during exhaustive maximal two‐legged cycling
Study: 6336641
Drug: Bicozamycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicozamycin (500 mg orally four times daily for 3 days)
Study: 29265040
Drug: Pharmaceutical Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Care Group (PC)
Study: 24400655
Drug: Alogliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin plus Metformin (A+M) 12.5/500 mg BID
Study: 24400655
Drug: Alogliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin plus Metformin (A+M) 12.5/1000 mg BID
Study: 24400655
Drug: Alogliptin (A)
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin (A) 12.5 mg BID
Study: 24400655
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 500 mg BID
Study: 24400655
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 1000 mg BID
Study: 24400655
Drug: Alogliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin plus Metformin (A+M)
Study: 24400655
Drug: Alogliptin (A)
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin (A) and Metformin (M) monotherapies
Study: 22932329
Drug: Bipolar coagulation
Normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar coagulation therapy
Study: 11403192
Drug: 1% cidofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% cidofovir cream
Study: 3386087
Drug: Cisapride 15
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride 15 mg/day
Study: 3386087
Drug: Cisapride 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 7.5 mg/day
Study: 19120074
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (Ganciclovir and valganciclovir) for 3 weeks
Study: 19120074
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (Ganciclovir and valganciclovir)
Study: 17805109
Drug: Intraoperative topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative topical Sensorcaine
Study: 14754739
Drug: EndoPearl adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoPearl adjunct to bioabsorbable interference screw fixation
Study: 10999089
Drug: benidipine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine 4 mg/day
Study: 10999089
Drug: benidipine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine 8 mg/day
Study: 10999089
Drug: benidipine 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine 4-8 mg/day
Study: 7007454
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folate tablets (Group B)
Study: 7007454
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthwash and tablets (Group A)
Study: 7007454
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthwash and 5 mg folate tablets (Group B)
Study: 26053853
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/HCTZ 12.5 mg (NLSD)
Study: 26053853
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/HCTZ 12.5 mg (NLSD)
Study: 26053853
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg (NLSD)